In the GEMRITUX (Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy) randomized controlled trial (87), including a cohort of 58 patients positive for anti-PLA2R-specific autoantibodies randomly treated with rituximab or conservative therapy, epitope spreading strongly correlated with serum titer of anti-PLA2R autoantibodies The absence of epitope spreading at onset was an independent predictor of remission at 6 months and at last follow-up (median of 23 months) (88). The gene discussed is PLA2R1; the disease is idiopathic membranous glomerulonephritis.